$AIM

Thermo Fisher Scientific (TMO) has partnered with AIM ImmunoTech to conduct a Phase 3 cancer trial, which is a significant advancement in their oncology program. This partnership is expected to enhance both companies' profiles in the biotech and pharmaceutical sectors. The collaboration indicates strong potential for innovative cancer therapies, which could improve TMO’s revenue streams. Investors may view this partnership as a positive step forward in TMO’s growth strategy. Overall, the market sentiment surrounding this news leans bullish, reflecting optimism about future developments in cancer treatment.

Aimia Inc. reported its Q4 earnings for 2025, showcasing remarkable growth in revenue and an increase in customer loyalty program participation. The company's focus on cost control and expansion into new markets contributed to a 15% year-over-year increase in profits. Management is optimistic about the upcoming quarters, with projections for sustained growth driven by strategic partnerships. Analysts view the results as a strong indicator of Aimia's solid positioning in the competitive landscape. Overall, Aimia's robust financial health and strategic direction have led to a positive market outlook for the company.